September 14, 2021
Novocure Announces Clinical Trial Collaboration with Roche to Evaluate Tumor Treating Fields as Part of a Novel Combination for the First-line Treatment of Metastatic Pancreatic Cancer
ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with Roche (SIX: RO. ROG; OTCQX: RHHBY), to develop Tumor Treating Fields (TTFields) together with Roche’s anti-PD-L1 therapy, atezolizumab, in metastatic pancreatic ductal adenocarcinoma (mPDAC). Pancreatic ductal adenocarcinoma (PDAC) is the most… Read More
learn more
September 9, 2021
FDA Grants Breakthrough Device Designation to the NovoTTF-200T™ System for Advanced Liver Cancer
NovoTTF-200T is a Tumor Treating Fields delivery system intended for use together with atezolizumab and bevacizumab for the treatment of patients with advanced liver cancer ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced the United States Food and Drug Administration (FDA) has granted breakthrough designation to the NovoTTF-200T… Read More
learn more
September 2, 2021
Novocure to Participate in the 2021 Wells Fargo Virtual Healthcare Conference
ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that Ashley Cordova, Chief Financial Officer, and Pritesh Shah, Chief Commercial Officer, will participate in the 2021 Wells Fargo Virtual Healthcare Conference on September 10, 2021. Ms. Cordova and Mr. Shah will take part in a fireside chat at 10:40 a.m. Read More
learn more
September 1, 2021
Novocure Appoints Bill Burke as Chief Human Resources Officer
ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that William (Bill) Burke has been promoted to Chief Human Resources Officer, effective September 1, 2021. This appointment reflects the importance of Novocure’s team members to our anticipated growth. Mr. Burke joined Novocure in 2014 and most recently served as the… Read More
learn more
